Evidence for therapy efficacy of such agents in urinary bladder cancer is lacking and it has been claimed that there might, in several cases, be resistance.5–8 It might therefore be, as an alternative to tyrosine kinase inhibitors and “naked” antibodies, beneficial to target the extracellular domains of EGFR and/or HER2 in metastatic urinary bladder cancer patients with molecules that deliver suitable radionuclides not only for whole body receptor mapping and dosimetry but also for radionuclide therapy. The gene discussed is ERBB2; the disease is urinary bladder cancer.